WHO IS THE AVLS PRO VENOUS REGISTRY?

By Marlin Schul, MD, MBA, RVT, FAVLS, DABVLM

The AVLS PRO Venous Registry has grown exponentially. In 2021, we saw an increase in the number of patients and procedures. This growth is largely due to the compounding of data by existing AVLS providers. Currently nearly 200 providers are in our Registry. We need as many AVLS members contributing data as possible.

The research generated from the Registry goes beyond interesting articles to read in our Journal. The data contributed by our members and the resulting research conducted will support and defend our field of practice against the continuing efforts of CMS and other payers to reduce payments – or even decide that there isn’t enough evidence supporting the health outcomes of treating pre-ulcer disease to justify any payments.

Total Records in the Database

Q1 2021

Patients: 180,573

Chemical Ablation: 205,955

Conservative Therapy: 9,271

Cyanoacrylate: 4,097

Endovenous Laser Ablation: 31,356

Mechanochemical Ablation: 6

Radio Frequency Ablation: 111,028

Sclerotherapy: 240,520

Surgery (Phlebectomy): 3,541

Q1 2022

Patients: 276,611

Chemical Ablation: 270,767

Conservative Therapy: 187,616

Cyanoacrylate: 7,741

Endovenous Laser Ablation: 41,856

Mechanochemical Ablation: 22

Radio Frequency Ablation: 161,918

Sclerotherapy: 299,771

Surgery (Phlebectomy): 49,154

To learn more about becoming an AVLS PRO Venous Registry data provider, please contact Michael Thompson, Director of Research: mthompson@myavls.org